DNMT3A and colorectal carcinoma: Given that the impaired expression of MEIS1 contributed to elevated IC50 of oxaliplatin and the essential role of ELFN1-AS1/EZH2-DNMT3a in controlling MEIS1 transcription, we attempted to transform this mechanism to pave a new way for clinical treatment of oxaliplatin resistant CRC patients.